By Melane Sampson
MAIA Biotechnology (NYSE American: MAIA) is focusing on the development and commercialization of breakthrough telomere-targeting immunotherapies: potential first-in-class drugs with novel mechanisms of action that aim to increase overall survival and improve the quality of life for patients with some of the hardest-to-treat cancers, including third-line non-small cell lung cancer (NSCLC).
“There is no established standard of care for third-line NSCLC, which affects roughly 50,000 individuals per year in the U.S. alone—a very high unmet medical need,” Vlad Vitoc, MD, MBA, founder and CEO of MAIA, says in an interview with BioTuesdays. “These patients are resistant to checkpoint inhibitors and chemotherapy. Virtually nothing works for them.”
MAIA’s lead program is ateganosine, a small-molecule telomere-targeting agent previously known as THIO. The investigational therapy represents a new scientific approach to cancer treatment and is one of the only direct telomere-targeting anticancer agents in clinical development. The company is currently evaluating ateganosine for its activity in NSCLC, with other cancer indications already being considered for future studies.
Dr. Vitoc explains that telomeres are protective caps made of DNA, located at the ends of chromosomes. Their specific function is to protect chromosome integrity during the course of the cell division cycle. Telomeres are built and maintained by the enzyme telomerase, which is present in all normal cells at the beginning of life. After around the first year of age, as telomeres reach their maximum length, telomerase activity is significantly reduced. From this point on, with each cell division, the telomeres lose a bit of length until old age, when they become critically short.
“In approximately 85% of cancers, telomerase becomes reactivated, enabling cancer cells to elongate their telomeres and reach a state of replicative immortality—meaning they continue to divide indefinitely and the cancer grows,” Dr. Vitoc says. “This is where ateganosine comes in.”
Ateganosine is designed to exploit this replicative mechanism. The molecule mimics guanine, one of the building blocks of DNA, and is incorporated into telomeres by the telomerase enzyme present in cancer cells. Once integrated into the telomeric DNA, the compound compromises telomere structure and function, causing the protective cap at the end of the chromosome to collapse.
“When ateganosine is incorporated into the telomere, the structure becomes unstable and the chromosomes are effectively uncapped,” Dr. Vitoc says. “That leads to rapid tumor cell death.”
He adds that beyond its direct anticancer effect, the therapy may also stimulate the immune system. The telomeric damage created by ateganosine produces micronuclei containing modified DNA fragments that can activate immune pathways.
“This mechanism generates a strong immunogenic signal, activating both the innate immune sensing pathways and adaptive T-cell responses,” Dr. Vitoc notes.
MAIA’s preclinical studies suggest the approach works particularly well in combination with checkpoint inhibitors. In animal models, sequential treatments with ateganosine, followed by anti-PD-1 or anti-PD-L1 therapies, resulted in substantial tumor regression and long-lasting immune memory.
The combination appears to convert immunologically cold tumors into hot tumors that respond to checkpoint inhibitors. “We have seen profound and durable tumor responses in multiple models,” Dr. Vitoc says.
The company is currently advancing ateganosine in several clinical trials. The ongoing Phase 2 study, THIO-101, is evaluating ateganosine followed by the checkpoint inhibitor Libtayo (cemiplimab) in patients with NSCLC whose disease has progressed after checkpoint inhibitor therapy.
Results reported to date from the study suggest the regimen could significantly improve outcomes for this heavily treated population.
“In the THIO-101 trial, we observed a disease control rate of approximately 88% and an overall response rate of 38%,” Dr. Vitoc highlights. “Historically, chemotherapy produces response rates of around 6% in this patient population.”
Most notably, the study showed a median overall survival of 17.8 months, compared with roughly five to six months observed with existing treatments.
“These results represent an approximate threefold improvement in survival compared with the current standard of care,” Dr. Vitoc says.
He points out that this encouraging Phase 2 data helped support the launch of MAIA’s Phase 3 THIO-104 trial. The study is evaluating ateganosine in combination with Libtayo versus investigator’s choice of chemotherapy in patients with third-line NSCLC who are resistant to both chemotherapy and checkpoint inhibitors.
“The primary endpoint is overall survival, which remains the gold standard for regulatory approval,” he adds.
The trial is designed to enroll approximately 150 patients in the combination arm and 150 patients receiving chemotherapy. While the study is powered to detect a more modest improvement in survival, the company is optimistic that the previously observed data could translate into substantially longer outcomes.
“Our target improvement in the Phase 3 study is from about 5.8 months to 7.8 months in median survival,” Dr. Vitoc says. “But based on the Phase 2 data, we believe survival could ultimately exceed 12 months and potentially approach 18 months.”
The company has also received regulatory designations and support for the program. Ateganosine has been granted Fast Track designation by the FDA for the treatment of third-line NSCLC. In addition, MAIA has secured multiple orphan drug designations for other tumor types, including small cell lung cancer, hepatocellular carcinoma, and malignant gliomas.
“These designations reflect the significant unmet medical need in these cancers and support our regulatory strategy moving forward,” Dr. Vitoc asserts.
MAIA is also expanding the potential clinical reach of the therapy through collaborations with several pharmaceutical partners. The company has a clinical supply agreement with Regeneron Pharmaceuticals (NASDAQ: REGN) for Libtayo in the THIO-101 NSCLC study, as well as additional collaborations with BeOne Medicines (NASDAQ: ONC; HKEX: 06160; SSE: 688235) and Roche (SIX: RO, ROG; OTCQX: RHHBY) to evaluate ateganosine in combination with other checkpoint inhibitors across several tumor types.
Dr. Vitoc points out that checkpoint inhibitors have become the backbone of cancer immunotherapy. MAIA’s strategy is to position ateganosine as a foundational therapy that enhances the activity of these agents.
Beyond lung cancer, the company plans to explore the therapy in colorectal cancer, liver cancer, small cell lung cancer, and brain tumors. “At this stage, we have five clinical studies either ongoing or in the planning stage,” Dr. Vitoc says.
In parallel, MAIA is developing a second generation of telomere-targeting agents designed to expand the platform and potentially improve selectivity and anticancer activity.
“In our discovery program, we have generated more than 80 molecules with similar mechanisms of action,” Dr. Vitoc says. “Several of them have demonstrated significantly greater potency in preclinical testing.”
He indicates that the company’s goal is to build a broader franchise around telomere-targeting therapies, potentially addressing multiple major cancer indications. “Our vision is to establish a new therapeutic category in oncology.”
The commercial opportunity could also be significant. Third-line NSCLC represents tens of thousands of patients annually in the U.S. alone, Dr. Vitoc emphasizes, with few effective treatment options currently available. “If ateganosine becomes the standard of care in this setting, the commercial potential could be substantial.”
MAIA expects interim results from the Phase 3 trial in 2027, which could potentially support regulatory approval if the survival benefit is confirmed.
With a strong leadership team and having completed a successful raise in March 2026, Dr. Vitoc says MAIA is financially stable. The company has just under $60 million in market capitalization. “We are more than capable of creating value alongside a very important therapeutic development like our ateganosine program.”
He concludes, “If we can demonstrate strong results in advanced disease, the next step would be to move this regimen into earlier-stage cancers where a cure is truly possible—our goal is to bring a therapy to patients that will meaningfully improve and extend their lives.”
• • • • •
To connect with MAIA Biotechnology or any other companies featured on BioTuesdays, send us an email at editor@biotuesdays.com.
